The B-Raf Status of Tumor Cells May Be a Significant Determinant of Both Antitumor and Anti-Angiogenic Effects of Pazopanib in Xenograft Tumor Models

Pazopanib is an FDA approved Vascular Endothelial Growth Factor Receptor inhibitor. We previously reported that it also inhibits tumor cell B-Raf activity in an experimental brain metastatic setting. Here, we determine the effects of different B-Raf genotypes on pazopanib efficacy, in terms of prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Gril, Brunilde, Palmieri, Diane, Qian, Yong, Anwar, Talha, Ileva, Lilia, Bernardo, Marcelino, Choyke, Peter, Liewehr, David J., Steinberg, Seth M., Steeg, Patricia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187787/
https://www.ncbi.nlm.nih.gov/pubmed/21998674
http://dx.doi.org/10.1371/journal.pone.0025625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187787/
https://www.ncbi.nlm.nih.gov/pubmed/21998674
http://dx.doi.org/10.1371/journal.pone.0025625

Ejemplares similares